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Abstract
Purpose Next to hypertrophy, hypertrophic cardiomyop-
athy (HCM) is characterized by alterations in myocardial
energetics. A small number of studies have shown that
myocardial external efficiency (MEE), defined by exter-
nal work (EW) in relation to myocardial oxidative
metabolism (MVO2), is reduced. The present study was
conducted to identify determinants of MEE in patients
with HCM by use of dynamic positron emission tomog-
raphy (PET) and cardiovascular magnetic resonance
imaging (CMR).
Methods Twenty patients with HCM (12 men, mean age:
55.2 ± 13.9 years) and 11 healthy controls (7 men, mean
age: 48.1 ± 10 years) were studied with [11C]acetate PET to
assess MVO2. CMR was performed to determine left
ventricular (LV) volumes and mass (LVM). Univariate
and multivariate analyses were employed to determine
independent predictors of myocardial efficiency.
Results Between study groups, MVO2 (controls: 0.12 ±
0.04 ml·min−1·g−1, HCM: 0.13 ± 0.05 ml·min−1·g−1, p =
0.64) and EW (controls: 9,139 ± 2,484 mmHg·ml, HCM:
9,368 ± 2,907 mmHg·ml, p = 0.83) were comparable,
whereas LVM was significantly higher (controls: 99 ± 21 g,
HCM: 200 ± 76 g, p < 0.001) and MEE was decreased in
HCM patients (controls: 35 ± 8%, HCM: 21 ± 10%, p <
0.001). MEE was related to stroke volume (SV), LV
outflow tract gradient, NH2-terminal pro-brain natriuretic
peptide (NT-proBNP) and serum free fatty acid levels (all
p < 0.05). Multivariate analysis revealed that SV (ß = 0.74,
p < 0.001) and LVM (ß = −0.43, p = 0.013) were
independently related to MEE.
Conclusion HCM is characterized by unaltered MVO2,
impaired EW generation per gram of myocardial tissue and
subsequent deteriorated myocardial efficiency. Mechanical
external efficiency could independently be predicted by SV
and LVM.
Keywords Myocardial efficiency . Oxygen consumption .
[11C]Acetate . Hypertrophic cardiomyopathy . Imaging
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic cardiac
disease phenotypically expressed by left ventricular (LV)
hypertrophy, which predominantly affects the interventricular
septum [1]. In addition, HCM is characterized by alterations
in myocardial energy metabolism. Ishiwata et al. demon-
strated that cardiac work in relation to oxidative metabolism,
i.e. myocardial efficiency, was reduced not only in the
hypertrophied septum but also in the lateral wall [2].
Similarly, an impaired energetic status as reflected by the
phosphocreatine to adenosine triphosphate ratio, derived
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by 31P spectroscopy, has been documented in different stages
of the disease process [3–6]. Although prognostic data
related to an impaired energetic state in HCM are lacking,
in analogy with other cardiomyopathies, it is believed to be
of prognostic relevance [7, 8]. Insights into the mechanism
and causative factors of altered energy metabolism could
therefore be of clinical importance in risk stratification and
the development and application of (new) therapeutic
approaches. Recent advances in imaging techniques offer
the possibility to accurately assess myocardial oxygen
consumption (MVO2), regional mechanical work and tissue
characteristics non-invasively using dynamic positron emis-
sion tomography (PET) [9, 10] and cardiac magnetic
resonance imaging (CMR) [11–13], respectively. The present
study was conducted to identify the determinants of impaired
myocardial energetics and efficiency in patients with
symptomatic HCM with the use of these currently available
advanced imaging techniques.
Methods
Subjects
Twenty patients with non-familial HCM were enrolled in the
study. HCM was diagnosed according to the presence of a
hypertrophied and non-dilated left ventricle (LV) on two-
dimensional echocardiography (maximal wall thickness
>15 mm in adults), in the absence of other systemic or cardiac
causes of LV hypertrophy [14]. The pattern of hypertrophy
was asymmetrical septal hypertrophy in all patients. Coro-
nary angiography was performed to exclude coronary artery
disease (CAD) and myocardial bridging. All patients were
using beta blockers or calcium channel blocking agents,
which were not discontinued. Eleven healthy adults with
normal physical examination, two-dimensional echocardiog-
raphy and electrocardiogram without a relevant medical
history served as controls. The study protocol was approved
by the Medical Ethics Committee of the VU University
Medical Center, Amsterdam, The Netherlands.
Imaging protocols
PET
All scans were obtained under resting conditions after
overnight fasting, in two-dimensional mode, by use of an
ECAT EXACT HR + scanner (Siemens/CTI, Knoxville,
TN, USA). A transmission scan was performed using three
rod sources filled with 68Ga/68Ge solution. Subsequently,
550 MBq of [11C]acetate was injected and simultaneously a
dynamic 29-frame acquisition was performed lasting
48 min (12×10, 3×20, 4×60, 3×120 and 7×300 s). During
the PET acquisition, venous blood was drawn and NH2-
terminal pro-brain natriuretic peptide (NT-proBNP, expressed
in ng/l), haemoglobin (Hb), free fatty acids (FFA), glucose
and lactate levels were determined. Blood pressure and heart
rate were recorded at regular intervals during the PET
studies.
CMR
CMR studies were performed on a 1.5-T whole-body
scanner (Magnetom Sonata, Siemens, Erlangen, Germany),
using a six-channel phased array body coil.
After survey scans, a retro-triggered, balanced steady-
state free precession gradient-echo sequence was used for
cine imaging. Image parameters were: slice thickness
5 mm, slice gap 5 mm, temporal resolution <50 ms,
repetition time 3.2 ms, echo time 1.54 ms, flip angle 60°
and a typical image resolution of 1.3*1.6 mm. The number
of phases within the cardiac cycle was set at 20.
After the four-, three-, and two-chamber view cines were
obtained, a stack of six to ten transversely oriented slices was
planned on an end-diastolic (ED) two-chamber view at the
level of the lower leading edge of the mitral valve annulus to
cover the left atrium (LA) [15]. Then, a stack of 10–12 short-
axis slices were acquired for full coverage of the LV used for
assessing LV volumes, mass and ejection fraction (see Fig. 1).
The method of planning the image acquisition for LV
coverage has been described previously [16]. Cine images
were acquired during one breath-hold in mild expiration.
Aortic flow measurements were performed with a non-
breath-hold, retrospective, ECG-triggered, phase-contrast
velocity mapping sequence with the encoding velocity set
at 150 cm·s−1. The image plane was planned on a coronal
view of the thorax, perpendicular to the ascending aorta.
Acquisition of the entire cardiac cycle was achieved by
setting the acquisition window to 120% of the cardiac cycle
length. To minimize the effects of eddy currents and
Maxwell gradients on velocity acquisition, patients were
positioned in the isocentre of the scanner.
Cine imaging with myocardial tagging was applied to
create non-invasive markers (tags) within the myocardium
for calculation of strain [11]. Three short-axis tagged
images with complementary spatial modulation of magne-
tization tagging for improved strain calculations were
acquired as previously described [17].
Delayed contrast enhanced (DCE) images were acquired
10–15 min after intravenous administration of 0.2 mmol/kg
gadolinium, by using a two-dimensional segmented inversion
recovery prepared gradient-echo sequence. Inversion recovery
time was 250–300 ms. Figure 1 illustrates examples of CMR
cine and tagging images during ED and end-systole (ES) as
well as a DCE image and phase-contrast velocity map, all
representative for the HCM phenotype.
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Echocardiography
Transthoracic two-dimensional echocardiography was per-
formed on a Vivid 7 (General Electrics-Vingmed, Milwaukee,
WI, USA). Systolic anterior motion of the mitral valve (SAM)
was qualitatively graded, whereas mitral regurgitation (MR)
was quantitatively graded on a scale from 0 (no regurgitation)
to 4 (severe regurgitation). The pressure gradient across the
LV outflow tract (LVOTG) was estimated by use of pulsed-
wave Doppler.
Data analysis
PET
Data were transferred to a SUN workstation and analysed
using Siemens/CTI software and MATLAB. Regions of
interest (ROIs) were defined manually on the maximum
intensity [11C]acetate short-axis images at the basal,
midventricular and apical level of the LV according to a
13-segment model as described previously in detail [18].
This set of ROIs was projected onto the [11C]acetate images
to generate time-activity curves (TAC). The linear myocar-
dial washout part of the [11C]acetate TAC was determined
automatically and fitted in a monoexponential fashion to
determine Kmono, which corresponds to oxidative metabo-
lism [10]. For each individual PET data set, average, septal
and lateral wall Kmono values were determined. Average
Kmono was derived from the weighted mean of all segmental
Kmono values, whereas regionally corresponding segments
were combined to generate septal and lateral wall Kmono. To
derive MVO2 from average Kmono, a relationship between
Kmono and myocardial oxygen metabolism (ml·min
−1·g−1),
previously established in humans, was used, where
Kmono ¼ 0:0027 MVO2 þ 0:0197ð Þ [19]. Since MVO2
expresses the oxygen consumption per minute, MVO2 per
beat was also determined (MVO2(beat)=MVO2/HR).
CMR
LV volume analysis was performed by manually drawing
epicardial and endocardial contours on all ED and ES LV
S
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Fig. 1 Examples of CMR short-axis cine images at end-diastole (a)
and end-systole (a’). CMR short-axis tagging images at end-diastole
(b) and end-systole (b’) with characteristically decreased septal
deformation compared to the lateral wall at end-systole. c CMR
short-axis delayed contrast enhancement image with a patchy
appearance. d Aortic velocity-encoded phase-contrast flow map. S
septum, L lateral wall
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short-axis images. Global LV function parameters, includ-
ing ED volume (LVEDV), ES volume (LVESV), ejection
fraction (LVEF) and myocardial mass, were then derived
from the cine images with use of the MASS software
package (Medis, Leiden, The Netherlands). For LA
diameter analysis, epicardial contours were drawn on all
LA data sets in ES. The forward SV was obtained from the
velocity-encoded phase-contrast aortic flow maps by
dividing the forward cardiac output by heart rate (HR).
The tagging images were used to generate circumferential
strain curves for each myocardial segment. Subsequently,
circumferential shortening (Ecc), which reflects maximum
myocardial contraction, was derived for each segment from
the strain curves [17]. Since circumferential shortening is
determined by the shortening of myofibres, Ecc is expressed
as a negative value. Similar average, septal and lateral wall
segmentation was used as described for the PET data.
Finally, each myocardial segment was evaluated for the
presence of hyperenhancement, which was defined as an area
of signal enhancement greater than 5 SD of the signal of non-
enhanced myocardium. The extent of DCE was expressed as
the percentage of the total myocardial tissue area studied.
Calculation of myocardial efficiency
As illustrated by Fig. 2, total mechanical energy is
represented by the area between the end-systolic pressure-
volume relationship (ESPVR), the end-diastolic pressure-
volume relationship (EDPVR) and the pressure-volume
loop of the cardiac cycle. The pressure-volume area (PVA)
was defined as the sum of external work (EW) and potential
energy (PE). EW was determined according to the factor of
mean arterial pressure (MAP) and forward stroke volume
(SV). In the HCM group, individually obtained estimations
of the LVOTG were added to the MAP to ensure accurate
estimations of actual LV pressures in the case of outflow
tract obstruction. Since the end-diastolic pressure-volume
point was not available, it was set to zero. The slope of the
ESPVR, Ees(sb) expressed in mmHg ml
−1, was estimated by
use of a previously validated single-beat method [20].
Subsequently, the x-axis intercept of the ESPVR was
calculated from which point PE and, thus, PVA could be
calculated. When the x-axis intercept was negative, it was
set to zero. The caloric equivalent of 1 mmHg · ml equals
1.33 · 10−4J, whereas 1 ml of O2 is ≈ 20 J. Subsequently,
mechanical external efficiency (MEE) was calculated
according to the equation below [10].
MEE ¼ EW  HR  1:33  10
4
MVO2  LVM  20
Mechanical efficiency (ME) was similarly calculated by
substituting EW for PVA area. In addition, the ratio between
EW and PVA served as an index for mechanical conversion
efficiency. Regional efficiency was determined as the ratio
between regional Ecc and the corresponding MVO2(beat),
where more negative values indicate increased efficiency.
Statistics
Results are displayed as mean ± SD. Differences between
the patients with HCM and controls were assessed by the
unpaired Student’s t test. The significance of intraindividual
differences between the septum and lateral wall were
determined with the paired Student’s t test. Correlations
between variables were evaluated with linear equation
analysis. Univariate and multivariate analyses were
employed to determine independent predictors of MEE. In
the multivariate analyses, stepwise manual backward
selection was applied with a removing probability for each
variable of≥0.1. All tests were two-sided and p values<
0.05 were considered statistically significant. Analyses
were performed using SPSS 15.0 (Chicago, IL, USA).
Results
Baseline characteristics of both study groups are shown in
Table 1. LV mass (LVM), left atrial size (LA size), NT-
proBNP, serum FFA and DCE were all significantly
increased in the HCM group. SAM was present in 12
HCM patients, whereas a total of 16 patients exhibited a
certain degree of MR (grade 1, n=5; grade 2, n=9; grade 3,
n=2; grade 4, n=0). No significant difference between
groups was found for sex, age, body surface area (BSA),
SV, LV ejection fraction (LVEF), Hb, and serum lactate and
glucose levels.
Fig. 2 Schematic representation of a pressure-volume area (PVA).
EW external work, PE potential energy, ESPVR end-systolic
pressure-volume relationship, EDPVR end-diastolic pressure-
volume relationship
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Haemodynamics
Haemodynamic parameters obtained during PET for the
HCM and control groups are presented in Table 2. LV
outflow tract obstruction (peak LVOTG > 30 mmHg) was
present in 13 HCM patients. The LV outflow tract gradient
as well as mean LV pressures were significantly higher in
HCM patients (both p < 0.001), whereas arterial blood
pressures and heart rates were comparable.
Myocardial metabolism and contractile parameters
PET-derived estimates of MVO2 and MRI-obtained contrac-
tile parameters are also depicted in Table 2. MVO2 was
comparable between groups (p = 0.64), as well as Ees(sb) (p =
0.30). In addition, no significant differences were found
between groups for EW (p = 0.83), PE (p = 0.17) and PVA
(p = 0.54).
Myocardial efficiency
Table 3 lists the estimated efficiency values of HCM patients
and controls. MEE was significantly decreased in the HCM
group as compared to the control group (p < 0.001), as well
as ME (p < 0.001). In contrast, mechanical conversion
efficiency did not differ between groups (p = 0.80).
Determinants of MEE
The results of univariate and multivariate regression analyses
of MEE are depicted in Table 4. MEE was significantly and
positively correlated to SV, whereas an inverse correlation
was observed with LVOTG, NT-proBNP levels and FFA.
When multivariate analysis was performed, SV and LVM
remained independent predictors of MEE, and these two
factors could predict 83% of MEE values.
Regional myocardial metabolism and efficiency
Figure 3a represents MVO2 values for the septum and lateral
wall in HCM patients and control subjects. In the HCM
group, septal MVO2(beat) was significantly lower compared to
Table 1 Study population characteristics
HCM (n=20) Controls (n=11) p
Sex 12 men 7 men 0.85
Age (years) 55 ± 14 48 ± 10 0.15
BSA (m2) 2.1 ± 0.2 2.0 ± 0.2 0.72
LVM (g) 200 ± 76 99 ± 21 0.001
SV (ml) 87 ± 24 102 ± 26 0.12
LVEF (%) 61 ± 7 61 ± 5 0.98
LA size (mm) 144 ± 41 101 ± 21 0.003
NT-proBNP (ng·l−1) 619 ± 638 61 ± 53 0.001
Hb (mmol·l−1) 8.5 ± 0.4 8.3 ± 0.5 0.34
FFA (mmol·l−1) 0.70 ± 0.20 0.52 ± 0.23 0.041
Glucose (mmol·l−1) 5.2 ± 1.3 5.6 ± 0.7 0.29
Lactate (mmol·l−1) 1.10 ± 0.61 1.46 ± 0.65 0.15
DCE (%) 4.1 ± 2.4 0 < 0.001
BSA body surface area, LVM left ventricular mass, SV stroke volume,
LVEF left ventricular ejection fraction, SAM systolic anterior motion
of the mitral valve, LA size maximal left atrial size, NT-proBNP NH2-
terminal pro-brain natriuretic peptide, Hb haemoglobin, FFA free fatty
acids, DCE delayed contrast enhancement
Table 2 Haemodynamics, myocardial oxygen metabolism and contractile parameters
HCM Controls p
Haemodynamics
Systolic BP (mmHg) 128 ± 21 122 ± 12 0.48
Diastolic BP (mmHg) 70 ± 8 73 ± 9 0.46
LVOTG (mmHg) 22 ± 11 0 < 0.001
LVMAP (mmHg) 113 ± 23 89 ± 9 < 0.001
Heart rate (bpm) 63 ± 10 67 ± 11 0.31
Oxygen metabolism
MVO2 (ml·min
−1·g−1) 0.13 ± 0.05 0.12 ± 0.04 0.64
Contractile function
Ees(sb) (mmHg·ml
−1) 1.42 ± 0.61 1.15 ± 0.36 0.30
EW (mmHg·ml) 9,368 ± 2,907 9,139 ± 2,484 0.83
PE (mmHg·ml) 3,507 ± 1,216 2,921 ± 910 0.17
PVA (mmHg·ml) 12,875 ± 3,704 12,060 ± 3,004 0.54
BP blood pressure, LVOTG left ventricular outflow tract gradient, LVMAP left ventricular mean arterial pressure, MVO2 myocardial oxygen
consumption, Ees(sb) single-beat estimation of Ees, EW external work, PE potential energy, PVA pressure-volume area
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the lateral wall (1.82 ± 0.63 · 10−3ml·beat−1·g−1 and 1.91 ±
0.65 · 10−3ml·beat−1·g−1 respectively, p=0.006). In contrast,
septal MVO2(beat) in the control group was comparable to the
lateral wall (1.95 ± 0.55 · 10−3ml·beat−1·g−1 and 1.89 ± 0.57 ·
10−3ml·beat−1·g−1 respectively, p=0.69). Regional Ecc
values for the septum and lateral wall in the HCM and
control groups are depicted in Fig. 3b. In the HCM group,
septal Ecc averaged −13.0 ± 2.5% and was significantly
lower compared to the lateral wall (−15.8 ± 1.9%, p <
0.001), whereas in the control group Ecc did not display
regional differences (septum: −17.7 ± 1.8%, lateral wall:
−18.6 ± 2.6%, p = 0.22). Consequently, regional efficiency
of septum averaged −7,740 ± 2,927 and was significantly
lower compared to the lateral wall in the HCM group
(−8,917 ± 3,767, p = 0.006). In contrast, regional efficiency
in the control group was comparable between the septum
and lateral wall (−10,187 ± 3,507 and −10,924 ± 4,401,
respectively, p = 0.21) as illustrated by Fig. 3c. Between
groups, regional efficiency of the septum was significantly
decreased in the HCM group (p = 0.05), whereas the lateral
wall was comparable (p = 0.20).
Discussion
Myocardial oxygen consumption
The present study demonstrates that MVO2 in HCM
patients is comparable to controls, in line with invasive
investigations [21–23]. Similarly, previous non-invasive
[11C]acetate PET studies in HCM have demonstrated
MVO2 in HCM to be comparable to controls [24] or
slightly decreased [2, 25].
Contractile parameters
LV EW and PVA were also comparable between HCM and
controls. However, when corrected for LVM, EW and PVA
generated per gram of myocardium were significantly
decreased in HCM, in line with other invasive [22] and
non-invasive studies [2, 24]. Although not reaching
statistical significant, a trend towards an increased slope
of the ESPVR was observed in the HCM group, consistent
with an invasive study [26].
Table 3 Myocardial efficiency
HCM Controls p
Mechanical external efficiency (EW/MVO2) 21 ± 10% 35 ± 8% < 0.001
Mechanical efficiency (PVA/MVO2) 30 ± 14% 51 ± 12% < 0.001
Mechanical conversion efficiency (EW/PVA) 70 ± 6% 70 ± 7% 0.80
EW external work, PVA pressure-volume area, MVO2 myocardial oxygen consumption
Table 4 Univariate and multivariate regression analysis of determinants of MEE in patients with HCM
Univariate Multivariate
r p y β p
BSA 0.31 0.19
LA size −0.32 0.18
LVM −0.39 0.09 −0.052(x)+31.43 −0.425 0.013a
SV 0.58 0.008a 0.247(x) − 0.54 0.735 < 0.001a
LVEF 0.05 0.82
NT-proBNP −0.45 0.05a −0.009(x) + 26.02
FFA −0.52 0.03a −24.91(x)+37.14
LVOTG −0.54 0.02a −0.453(x) + 29.90
HR −0.42 0.06
Ecc(av) −0.16 0.52
Ees(sb) −0.06 0.82
DCE 0.23 0.42
BSA body surface area, LA size maximal left atrial size, LVM left ventricular mass, SV forward stroke volume, LVEF left ventricular ejection
fraction, NT-proBNP NH2-terminal pro-brain natriuretic peptide, FFA free fatty acids, LVOTG left ventricular outflow tract gradient, HR heart rate,
Ecc maximal circumferential contraction, Ees(sb) single-beat estimation of Ees, DCE delayed contrast enhancement
a Statistically significant
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Myocardial efficiency
In our series, EW and PVA are disproportionally decreased
in relation to oxygen usage in HCM, and therefore occur at
the expense of myocardial efficiency. Correspondingly, an
early invasive study by Thompson and co-workers in 13
patients with obstructive HCM revealed an MEE of 21%
[22]. Patients with LVH due to hypertension show similar
pseudonormalization of MVO2, accompanied by decreased
EW generation per gram of myocardium [27], suggesting
that mechanoenergetic uncoupling is a distinctive feature in
pathological hypertrophy [8, 10].
Whether impaired energetics in HCM is the consequence,
or the cause, of LVH remains unclear. Nonetheless, impaired
energy metabolism in HCM exists even in the absence of
hypertrophy, suggesting that compromised energetics precede
hypertrophy and may play a causal role in the development of
the HCM phenotype [28]. Concordantly, HCM cardiomyo-
cytes exhibit sarcomeric mutations resulting in inefficient
ATP utilization, with subsequent increased cost of force
generation and excess demand on myocytes [29].
The presence of microvascular dysfunction, a prominent
feature of HCM hearts [30], could also have a detrimental
impact on myocardial energetics. Microvascular dysfunc-
tion results in a blunted perfusion reserve [31, 32] and
subsequent myocardial ischaemia during stress [33], even
in the non-hypertrophied LV free wall [32]. Therefore, in
analogy to ischaemic heart disease due to CAD, repetitive
stunning of the myocardium in HCM might contribute to
deteriorating efficiency. Clearly, future studies are war-
ranted to investigate the interrelationships between micro-
vascular dysfunction and energetics in HCM.
In contrast to the above, mechanical conversion efficiency
remained unaltered between groups and was fairly consistent
with investigations in healthy adults [34, 35]. This indicates
that, despite impaired PVA due to inefficient energetics, the
transferral ratio from energy production to effective work is
preserved.
Regional efficiency
HCM hearts exhibit marked heterogeneity in regional
contractile properties [36–38]. Correspondingly, we have
shown that septal Ecc was significantly decreased as
compared to the lateral wall in the HCM group. Hence,
patients with HCM exhibited marked heterogeneity in
regional efficiency, especially due to deteriorated energet-
ics of the hypertrophied septum, whereas no significant
differences in regional efficiency were observed in the
control group. Interestingly, regional efficiency of the
lateral wall tended to be lower in HCM patients, when
compared to controls, also suggesting global impairment
of energetics in HCM patients. Ishiwata et al. have
produced similar results indicating a decreased work
production to oxygen expenditure ratio in the septum,
compared to the lateral wall in HCM [2]. A potential
explanation for these regional differences could be the
characteristic presence of myofibre disarray in HCM,
which can predominantly be found in the interventricular
septum located at the insertions with the right ventricle.
These oppositely contracting myocytes do not result in an
effective contraction pattern and therefore may contribute
to reduced MEE [39].
Determinants of MEE
Deteriorated MEE could independently be correlated to
smaller SV and increased LVM. Since SV and LVM are,
Fig. 3 a Regional MVO2 of the septum and lateral free wall in the
control and HCM groups. b Regional Ecc of the septum and lateral
free wall in the control and HCM groups. c Regional efficiency of the
septum and lateral free wall in the control and HCM groups. MVO2
myocardial oxygen consumption, HCM hypertrophic cardiomyopathy
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among other cardiac parameters, used to calculate MEE,
these results are not startling. Nevertheless, these factors
appear to be stronger determinants of MEE than LVOTG,
HR, BP or global strain, consequently suggesting a larger
potential for therapeutic interventions regarding preserva-
tion of SV and/or regression of LVM [24]. In addition,
increased haemodynamic pre- and afterload conditions,
reflected by increased NT-proBNP levels and outflow tract
obstruction, are also important factors related to MEE.
Surgical myectomy or alcohol ablation of the hypertrophied
septum in HCM reduces LVM by relief of LV outflow
obstruction, thereby decreasing extravascular compression
forces and inducing chamber remodelling [38, 41–43].
Therefore, regression of afterload-dependent LVH after
such a procedure may result in more favourable myocardial
energetics, possibly augmenting LV function and improving
prognosis in HCM patients.
Finally, where the extent of DCE has previously been
shown to be of independent predictive value to impaired
efficiency in patients with HCM [40], this could not be
reproduced in the present study.
Substrate metabolism
Next to higher FFA serum concentrations in HCM, we also
observed a significant inverse relationship between FFA
and MEE in these patients. These increased serum levels of
FFA may be related to an augmented sympathetic drive, a
well-documented phenomenon in cardiomyopathy and
heart failure. This change in metabolic milieu may induce
a metabolic switch from myocardial glucose to FFA
oxidation [24]. As glucose metabolism yields 11–13%
more ATP per unit of oxygen consumption compared with
FFA metabolism, this potential metabolic switch affects
mechanical efficiency and could explain the observed
correlation between MEE and serum FFA levels in the
present study [10]. On the other hand, Tadamura and co-
workers observed a switch from FFA to the more efficient
glucose oxidation in the presence of hypertrophy [25].
Although it is clear that substrate metabolism in HCM is
subject to changes and affects efficiency, future investiga-
tions in carefully selected study groups are warranted to
further demarcate this issue.
Study limitations
In the present study we used a previously obtained relation-
ship, obtained in healthy humans, to extrapolate MVO2 from
regional [11C]acetate clearance rates. It is however unknown
whether this relationship is valid in HCM patients, since
Kmono is dependent on arterial input, extraction and washout
of tracer as well as altered haemodynamic and metabolic
conditions of the myocardium.
Furthermore, with regard to the number of variables
included in the multivariate analysis, the cohort of HCM
patients was relatively small, as a result of which the output
should be interpreted with certain care. In addition, the
sustained use of medication could affect estimations of
actual myocardial efficiency [10], although it should be
noted that the currently studied cohort reflects the clinical
HCM population.
Finally, non-invasive estimation of work and contractile
function is hindered by some important factors. The
presence of valvular disease, such as MR in the HCM
group, could lead to overestimation of SV, and thus
efficiency, because part of the LV volume is ejected in the
low-pressured left atrium during systole. We largely
circumvented the latter issue by using forward SV only,
acquired by MRI flow measurements in the aortic root. In
addition, EW is represented as a rectangle in the present
study (Fig. 2), not taking into account the area under the
EDPVR curve. This results in overestimation of EW and
consequently MEE values, especially in patients with
decreased LV diastolic elastance (i.e. HCM patients). A
range of PV loops under different loading conditions (e.g.
by vena cava inferior occlusion) is warranted to accurately
determine the EDPVR and the ESPVR. However, with a
recently proposed single-beat method, Ees(sb) could be
obtained non-invasively. The LV end-systolic elastance
ensues a parabolic shape, and therefore a little under- or
overestimation of Ees cannot be ruled out.
Conclusion
Symptomatic HCM is characterized by unaltered MVO2,
impaired EW generation per gram of myocardial tissue and
subsequent deteriorated myocardial efficiency. MEE could
independently be predicted by SV and LVM.
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